Ruxolitinib sulfate

• CAT Number: I000388
• CAS Number: 1092939-16-6
• Molecular Formula: C17H20N6O4S
• Molecular Weight: 404.44
• Purity: ≥95%
• Synonyms: 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile sulfate
• Target: JAK
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: 3.3 nM/2.8 nM(JAK1/JAK2)
• IUPAC Name: 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;sulfuric acid
• InChI: InChI=1S/C17H18N6.H2O4S/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16;1-5(2,3)4/h6,8-12,15H,1-5H2,(H,19,20,21);(H2,1,2,3,4)
• InChIKey: LGJWVXWQCTZSGC-UHFFFAOYSA-N
• SMILES: C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OS(=O)(=O)O

Dehydrocrenatidine（Cat No.:I000388）is a bioactive alkaloid derived from the plant Radix Menispermi, known for its diverse pharmacological properties. It exhibits significant anti-inflammatory, analgesic, and antitumor activities, making it a subject of interest in medicinal research. Studies have shown that dehydrocrenatidine can inhibit the proliferation of various cancer cell lines and induce apoptosis through multiple signaling pathways. Additionally, it possesses antioxidant properties, contributing to its protective effects against oxidative stress. Dehydrocrenatidine’s multifaceted therapeutic potential highlights its promise as a candidate for developing new treatments in oncology and inflammation-related conditions.

Reference

[1]. Quintas-Cardama A, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115(15), 3109-3117.

[2]. Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 2012, 366(9), 799-807.